Karo Bio AB

Karo Bio is a drug discovery company focusing its research on the discovery and pre-clinical phases of drug development. Research is conducted primarily in the area of nuclear receptors. Nuclear receptors are proteins in the cell nucleus that act as receivers for a number of key hormones that enable the essential regulation of organs in the body. Through the understanding of nuclear receptors in drug design, new tissue selective drugscan be developed that have fewer or no side effects.

In addition to nuclear receptor research and development, Karo Bio also offers a novel approach to target validation and high-throughput screening with proprietary BioKey® technology. This proteomics-based drug discovery technology is ideal for the development of screens for targets of unknown function and for targets difficult to screen by traditional methods.

Karo Bio was founded in through a joint venture between Cal Bio, Inc and SGI.

Activity:

Product / Technology type(s) covered:

- Bio
- Pharmaceuticals / Therapeutics
- Proteins
- Technology

Therapeutic targets:

- Cancer
- Cardiovascular
- Dermatology
- Diabetes
- Genetics
- Men's Health
- Women's Health

Markets Covered

a. HeadQuarter: Sweden

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees: 122

Turnover:

Amount:	Year:	Currency:
136900000	2001	SEK

Year founded: 1987